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AbsTrACT
Introduction endometrial cancer is one of the most 
commonly diagnosed cancers in women. although there 
is a hereditary component to endometrial cancer, most 
cases are thought to be sporadic and lifestyle related. 
The aim of this study was to systematically review 
prospective and retrospective case–control studies, 
meta- analyses and genome- wide association studies to 
identify genomic variants that may be associated with 
endometrial cancer risk.
Methods We searched MeDline, embase and cinahl 
from 2007 to 2019 without restrictions. We followed 
PrisMa 2009 guidelines. The search yielded 3015 hits 
in total. Following duplicate exclusion, 2674 abstracts 
were screened and 453 full- texts evaluated based on our 
pre- defined screening criteria. 149 articles were eligible 
for inclusion.
results We found that single nucleotide polymorphisms 
(snPs) in HNF1B, KLF, EIF2AK, CYP19A1, SOX4 and 
MYC were strongly associated with incident endometrial 
cancer. nineteen variants were reported with genome- 
wide significance and a further five with suggestive 
significance. no convincing evidence was found for the 
widely studied MDM2 variant rs2279744. Publication 
bias and false discovery rates were noted throughout the 
literature.
Conclusion endometrial cancer risk may be influenced 
by snPs in genes involved in cell survival, oestrogen 
metabolism and transcriptional control. larger cohorts 
are needed to identify more variants with genome- wide 
significance.
InTroduCTIon
Endometrial cancer is the most common gynae-
cological malignancy in the developed world.1 
Its incidence has risen over the last two decades 
as a consequence of the ageing population, fewer 
hysterectomies for benign disease and the obesity 
epidemic. In the USA, it is estimated that women 
have a 1 in 35 lifetime risk of endometrial cancer, 
and in contrast to cancers of most other sites, 
cancer- specific mortality has risen by approximately 
2% every year since 2008 related to the rapidly 
rising incidence.2
Endometrial cancer has traditionally been classi-
fied into type I and type II based on morphology.3 
The more common subtype, type I, is mostly 
comprised of endometrioid tumours and is 
oestrogen- driven, arises from a hyperplastic endo-
metrium, presents at an early stage and has an 
excellent 5 year survival rate.4 By contrast, type II 
includes non- endometrioid tumours, specifically 
serous, carcinosarcoma and clear cell subtypes, 
which are biologically aggressive tumours with 
a poor prognosis that are often diagnosed at an 
advanced stage.5 Recent efforts have focused on a 
molecular classification system for more accurate 
categorisation of endometrial tumours into four 
groups with distinct prognostic profiles.6 7
The majority of endometrial cancers arise through 
the interplay of familial, genetic and lifestyle factors. 
Two inherited cancer predisposition syndromes, 
Lynch syndrome and the much rarer Cowden 
syndrome, substantially increase the lifetime risk 
of endometrial cancer, but these only account for 
around 3–5% of cases.8–10 Having first or second 
degree relative(s) with endometrial or colorectal 
cancer increases endometrial cancer risk, although 
a large European twin study failed to demonstrate a 
strong heritable link.11 The authors failed to show 
that there was greater concordance in monozygotic 
than dizygotic twins, but the study was based on 
relatively small numbers of endometrial cancers. 
Lu and colleagues reported an association between 
common single nucleotide polymorphisms (SNPs) 
and endometrial cancer risk, revealing the potential 
role of SNPs in explaining part of the risk in both 
the familial and general populations.12 Thus far, 
many SNPs have been reported to modify suscepti-
bility to endometrial cancer; however, much of this 
work predated genome wide association studies 
and is of variable quality. Understanding genetic 
predisposition to endometrial cancer could facil-
itate personalised risk assessment with a view to 
targeted prevention and screening interventions.13 
This emerged as the most important unanswered 
research question in endometrial cancer according 
to patients, carers and healthcare professionals in 
our recently completed James Lind Womb Cancer 
Alliance Priority Setting Partnership.14 It would be 
particularly useful for non- endometrioid endome-
trial cancers, for which advancing age is so far the 
only predictor.15
We therefore conducted a comprehensive system-
atic review of the literature to provide an overview 
of the relationship between SNPs and endometrial 
cancer risk. We compiled a list of the most robust 
endometrial cancer- associated SNPs. We assessed the 
applicability of this panel of SNPs with a theoretical 
polygenic risk score (PRS) calculation. We also crit-
ically appraised the meta- analyses investigating the 
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Figure 1 study selection flow diagram. *reasons: irrelevant articles, 
articles focusing on other conditions, non- gWas/candidate- gene study 
related articles, technical and duplicate articles. gWas, genome- wide 
association study. adapted from: Moher D, liberati a, Tetzlaff J, altman 
Dg, The PrisMa group (2009). Preferred reporting items for systematic 
reviews and Meta- analyses: The PrisMa statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097.
most frequently reported SNPs in MDM2. Finally, we described 
all SNPs reported within genes and pathways that are likely 
involved in endometrial carcinogenesis and metastasis.
MeThods
Our systematic review follows the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) collaboration 
2009 recommendations. The registered protocol is available 
through PROSPERO (CRD42018091907).16
search strategy
We searched Embase, MEDLINE and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) databases via 
the Healthcare Databases Advanced Search (HDAS) platform, 
from 2007 to 2018, to identify studies reporting associations 
between polymorphisms and endometrial cancer risk. Key words 
including MeSH (Medical Subject Heading) terms and free- text 
words were searched in both titles and abstracts. The following 
terms were used: “endomet*”,“uter*”, “womb”, “cancer(s)”, 
“neoplasm(s)”, “endometrium tumour”, “carcinoma”, “adeno-
sarcoma”, “clear cell carcinoma”, “carcinosarcoma”, “SNP”, 
“single nucleotide polymorphism”, “GWAS”, and “genome- wide 
association study/ies”. No other restrictions were applied. The 
search was repeated with time restrictions between 2018 and 
June 2019 to capture any recent publications.
eligibility criteria
Studies were selected for full- text evaluation if they were primary 
articles investigating a relationship between endometrial cancer 
and SNPs. Study outcome was either the increased or decreased 
risk of endometrial cancer relative to controls reported as an 
odds ratio (OR) with corresponding 95% confidence intervals 
(95% CIs).
study selection
Three independent reviewers screened all articles uploaded 
to a screening spreadsheet developed by Helena VonVille.17 
Disagreements were resolved by discussion. Chronbach’s α 
score was calculated between reviewers and indicated high 
consistency at 0.92. Case–control, prospective and retrospec-
tive studies, genome- wide association studies (GWAS), and both 
discovery and validation studies were selected for full- text eval-
uation. Non- English articles, editorials, conference abstracts 
and proceedings, letters and correspondence, case reports and 
review articles were excluded.
Candidate- gene studies with at least 100 women and GWAS 
with at least 1000 women in the case arm were selected to ensure 
reliability of the results, as explained by Spencer et al.18 To 
construct a panel of up to 30 SNPs with the strongest evidence 
of association, those with the strongest p values were selected. 
For the purpose of an SNP panel, articles utilising broad Euro-
pean or multi- ethnic cohorts were selected. Where overlapping 
populations were identified, the most comprehensive study was 
included.
data extraction and synthesis
For each study, the following data were extracted: SNP ID, 
nearby gene(s)/chromosome location, OR (95% CI), p value, 
minor or effect allele frequency (MAF/EAF), EA (effect allele) 
and OA (other allele), adjustment, ethnicity and ancestry, number 
of cases and controls, endometrial cancer type, and study type 
including discovery or validation study and meta- analysis. For 
risk estimates, a preference towards most adjusted results was 
applied. For candidate- gene studies, a standard p value of<0.05 
was applied and for GWAS a p value of <5×10-8, indicating 
genome- wide significance, was accepted as statistically signifi-
cant. However, due to the limited number of SNPs with p values 
reaching genome- wide significance, this threshold was then 
lowered to <1×10-5, allowing for marginally significant SNPs 
to be included. As shown by Mavaddat et al, for breast cancer, 
SNPs that fall below genome- wide significance may still be useful 
for generating a PRS and improving the models.19
We estimated the potential value of a PRS based on the most 
significant SNPs by comparing the predicted risk for a woman 
with a risk score in the top 1% of the distribution to the mean 
predicted risk. Per- allele ORs and MAFs were taken from the 
publications and standard errors (SEs) for the lnORs were 
derived from published 95% CIs. The PRS was assumed to have 
a Normal distribution, with mean 2∑βipI and SE, σ, equal to 
√2∑βi2pI(1−pi), according to the binomial distribution, where 
the summation is over all SNPs in the risk score. Hence the rela-
tive risk (RR) comparing the top 1% of the distribution to the 
mean is given by exp(Z0.01σ), where Z is the inverse of the stan-
dard normal cumulative distribution.
resulTs
The flow chart of study selection is illustrated in figure 1. In 
total, 453 text articles were evaluated and, of those, 149 arti-
cles met our inclusion criteria. One study was excluded from 
table 1, for having an Asian- only population, as this would make 
it harder to compare with the rest of the results which were all 
either multi- ethnic or Caucasian cohorts, as stated in our inclu-
sion criteria for the SNP panel.20 Any SNPs without 95% CIs 
were also excluded from any downstream analysis. Additionally, 
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SNPs in linkage disequilibrium (r2 >0.2) with each other were 
examined, and of those in linkage disequilibrium, the SNP with 
strongest association was reported. Per allele ORs were used 
unless stated otherwise.
Top snPs associated with endometrial cancer risk
Following careful interpretation of the data, 24 independent 
SNPs with the lowest p values that showed the strongest asso-
ciation with endometrial cancer were obtained (table 1).21–25 
These SNPs are located in or around genes coding for tran-
scription factors, cell growth and apoptosis regulators, and 
enzymes involved in the steroidogenesis pathway. All the SNPs 
presented here were reported on the basis of a GWAS or in one 
case, an exome- wide association study, and hence no SNPs from 
candidate- gene studies made it to the list. This is partly due to 
the nature of larger GWAS providing more comprehensive and 
powered results as opposed to candidate gene studies. Addition-
ally, a vast majority of SNPs reported by candidate- gene studies 
were later refuted by large- scale GWAS such as in the case of 
TERT and MDM2 variants.26 27 The exception to this is the 
CYP19 gene, where candidate- gene studies reported an associ-
ation between variants in this gene with endometrial cancer in 
both Asian and broad European populations, and this associa-
tion was more recently confirmed by large- scale GWAS.21 28–30 
Moreover, a recent article authored by O’Mara and colleagues 
reviewed the GWAS that identified most of the currently known 
SNPs associated with endometrial cancer.31
Most of the studies represented in table 1 are GWAS and the 
majority of these involved broad European populations. Those 
having a multi- ethnic cohort also consisted primarily of broad 
European populations. Only four of the variants in table 1 are 
located in coding regions of a gene, or in regulatory flanking 
regions around the gene. Thus, most of these variants would not 
be expected to cause any functional effects on the gene or the 
resulting protein. An eQTL search using GTEx Portal showed 
that some of the SNPs are significantly associated (p<0.05) with 
modified transcription levels of the respective genes in various 
tissues such as prostate (rs11263761), thyroid (rs9668337), 
pituitary (rs2747716), breast mammary (rs882380) and testic-
ular (rs2498794) tissue, as summarised in table 2.
The only variant for which there was an indication of a specific 
association with non- endometrioid endometrial cancer was 
rs148261157 near the BCL11A gene. The A allele of this SNP 
had a moderately higher association in the non- endometrioid 
arm (OR 1.64, 95% CI 1.32 to 2.04; p=9.6×10-6) compared 
with the endometrioid arm (OR 1.25, 95% CI 1.14 to 1.38; 
p=4.7×10-6).21
Oestrogen receptors α and β encoded by ESR1 and ESR2, 
respectively, have been extensively studied due to the assumed 
role of oestrogens in the development of endometrial cancer. 
O’Mara et al reported a lead SNP (rs79575945) in the ESR1 
region that was associated with endometrial cancer (p=1.86×10-
5).24 However, this SNP did not reach genome- wide significance 
in a more recent larger GWAS.21 No statistically significant asso-
ciations have been reported between endometrial cancer and 
SNPs in the ESR2 gene region.
AKT is an oncogene linked to endometrial carcinogenesis. It 
is involved in the PI3K/AKT/mTOR pro- proliferative signalling 
pathway to inactivate apoptosis and allow cell survival. The A 
allele of rs2494737 and G allele of rs2498796 were reported to 
be associated with increased and decreased risk of endometrial 
cancer in 2016, respectively.22 30 However, this association was 
not replicated in a larger GWAS in 2018.21 Nevertheless, given 
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Table 2 List of eQTL hits for the selected panel of SNPs
snP Id
significant 
eQTl for P Tissue other gene(s) other tissue(s)
rs17601876 GLDN 1.2e-08 Adipose – subcutaneous SPPL2A, DMXL2 Skin – sun exposed (lower leg); colon – sigmoid; cells – cultured 
fibroblasts; muscle – skeletal; spleen; skin – not sun exposed 
(suprapubic); nerve – tibial
CYP19A1 3.4e-07 Whole blood
CYP19A1 5.8e-06 Adipose – subcutaneous
rs3184504 TMEM116 1.7e-04 Adipose – subcutaneous ALDH2, LINC01405, 
ADAM1B
Oesophagus – mucosa; skin – not sun exposed (suprapubic); skin 
– sun exposed (lower leg); muscle – skeletal; artery – aorta; heart 
– atrial appendage; artery – tibial; colon – sigmoid; brain – nucleus 
accumbens (basal ganglia)
MAPKAPK5 2.6e-04 Adipose – subcutaneous
rs2747716 RP11- 624M8.1 4.2e-11 Pituitary HDDC2 Artery – tibial; pancreas; thyroid; brain – nucleus accumbens (basal 
ganglia); brain – substantia nigra; oesophagus – muscularis; nerve – 
tibial; Brain – caudate (basal ganglia); adipose – visceral (omentum); 
brain – spinal cord (cervical c-1); artery – aorta; brain – cortex; brain 
– hypothalamus; muscle – skeletal; brain – cerebellum; heart – left 
ventricle; brain – putamen (basal ganglia); brain – frontal cortex 
(BA9); brain – cerebellar hemisphere
RP11- 624M8.1 8.2e-11 Adipose – subcutaneous
HEY2 9.7e-10 Testis
HEY2 2.1e-09 Ovary
RP11- 624M8.1 1.7e-07 Breast – mammary tissue
RP11- 624M8.1 1.3e-06 Ovary
rs9668337 BHLHE41 9.0e-17 Thyroid RP11- 283G6.3 Cells – cultured fibroblasts
SSPN 1.1e-04 Thyroid
rs882380 SNX11 3.1e-25 Adipose – subcutaneous RP5- 890E16.5, CBX1, 
LRRC46, MRPL10, RP11- 
6N17.4, CDK5RAP3, SP6, 
PRR15L, RP5- 890E16.2, 
PNPO, RP11- 6N17.3, 
HOXB1, HOXB- AS1, 
NFE2L1
Skin – sun exposed (lower leg); cells – cultured fibroblasts; adipose 
– visceral (omentum); lung; skin – not sun exposed (suprapubic); 
pancreas; spleen; oesophagus – muscularis; artery – aorta; heart – 
atrial appendage; liver; colon – transverse; thyroid; artery – tibial; 
colon – sigmoid; oesophagus – gastro- oesophageal junction; 
stomach; muscle – skeletal; small intestine – terminal Ileum; 
prostate; brain – cerebellum; brain – cerebellar hemisphere; minor 
salivary gland; adrenal gland; oesophagus – mucosa
SNX11 1.0e-21 Whole blood
SNX11 1.2e-13 Breast – mammary tissue
COPZ2 9.3e-12 Testis
SKAP1 3.3e-08 Whole blood
HOXB2 2.6e-05 Adipose – subcutaneous
rs937213 EIF2AK4 4.7e-11 Adipose – visceral 
(omentum)
SRP14 Thyroid; oesophagus – mucosa; skin – sun exposed (lower leg); 
stomach; oesophagus – muscularis; pancreas; skin – not sun exposed 
(suprapubic); colon – transverse; adipose – subcutaneous; lung; 
colon – sigmoid; muscle – skeletal; nerve – tibial; whole blood; 
oesophagus – gastro- oesophageal junction; artery – tibial; adrenal 
gland; spleen; heart – left ventricle; heart – atrial appendage
EIF2AK4 3.4e-08 Breast – mammary tissue N/A
RP11- 521C20.5 5.4e-07 Testis N/A
RP11- 521C20.5 7.4e-07 Prostate N/A
rs2498794 AKT1 1.7e-30 Thyroid ZBTB42 Oesophagus – mucosa; artery – tibial; oesophagus – muscularis; 
skin – sun exposed (lower leg); skin – not sun exposed (suprapubic); 
cells – cultured fibroblasts; artery – aorta; oesophagus – gastro- 
oesophageal junction; adipose – subcutaneous; colon – sigmoid; 
colon – transverse; heart – atrial appendage
ADSSL1 5.5e-25 Testis
SIVA1 1.8e-07 Adipose – visceral 
(omentum)
ADSSL1 2.6e-05 Ovary
SIVA1 4.4e-05 Breast – mammary tissue
rs10835920 WT1- AS 5.5e-06 Spleen N/A Oesophagus -– muscularis
rs148261157 KIAA1841 1.3e-05 Oesophagus – muscularis N/A N/A
rs113998067 RSPO1 2.7e-10 Artery – tibial EPHA10, FHL3, DNALI1 Nerve – tibial; artery – aorta; colon – transverse
rs1129506 EVI2A 4.3e-20 Whole blood OMG, RAB11FIP4 Spleen; oesophagus – mucosa; artery – tibial; lung; artery – aorta; 
skin – sun exposed (lower leg); nerve – tibial; heart – atrial 
appendage; adipose – visceral (omentum); cells – cultured 
fibroblasts; liver; stomach; brain – amygdala; skin – not sun exposed 
(suprapubic); brain – caudate (basal ganglia); muscle – skeletal; 
colon – sigmoid
NF1 3.5e-09 Adipose – subcutaneous
NF1 2.2e-07 Thyroid
NF1 3.7e-07 Testis
rs673604 ZMYM1 7.0e-07 Adipose – subcutaneous RP4- 665N4.8, ZMYM4, 
KIAA0319L, TFAP2E
Skin – sun exposed (lower leg); oesophagus – muscularis; cells – 
EBV- transformed lymphocytes; oesophagus – mucosa; nerve – tibial; 
brain – cerebellum
MAP7D1 1.0e-05 Whole blood
rs1953358 LINC00520 1.5e-05 Skin – not sun exposed 
(suprapubic)
N/A N/A
rs8178648 PROS1 3.0e-04 Skin – sun exposed (lower 
leg)
N/A N/A
Top significant eQTL hits from different tissues are shown in the table. There were no significant hits reported for some SNPs which are hence not included in this table.
EBV, Epstein- Barr virus; SNP, single nucleotide polymorphism.
the previous strong indications, and biological basis that could 
explain endometrial carcinogenesis, we decided to include an 
AKT1 variant (rs2498794) in our results.
PTEN is a multi- functional tumour suppressor gene that 
regulates the AKT/PKB signalling pathway and is commonly 
mutated in many cancers including endometrial cancer.32 Loss- 
of- function germline mutations in PTEN are responsible for 
Cowden syndrome, which exerts a lifetime risk of endometrial 
cancer of up to 28%.9 Lacey and colleagues studied SNPs in the 
PTEN gene region; however, none showed significant differ-
ences in frequency between 447 endometrial cancer cases and 
439 controls of European ancestry.33
KRAS mutations are known to be present in endome-
trial cancer. These can be activated by high levels of KLF5 
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Table 3 Characteristics of studies that examined MDM2 SNP rs2279744
reference or (95% CI) P values eAF Ancestry Cases (n) Controls (n) eC type dataset(s)
Terry 200848 1.32 (1.11 to 1.56) 0.002 N/A European 591 1543 N/A NHS (Nurses’ Health Study), WHS (Women’s Health Study)
Ashton 200949 1.37 (1.06 to 1.79) N/A 0.56 Caucasian 191 291 All Hospital based
Nunobiki 200950 2.28 (2.02 to 2.54) 0.030 0.49 Japanese 102 95 All Hospital based
Ueda 200951 1.91 (1.5 to 3.47) 0.035 0.51 Japanese 119 108 All Hospital based
Wan 201143 1.54 (1.21 to 1.94) 0.000 N/A N/A N/A N/A N/A Walsh 2007,36 Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009
Li 201144 1.75 (1.16 to 2.63) 0.007 N/A European, 
Asian
1001 1889 N/A Walsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009
Knappskog 
201240
1.22 (1.03 to 1.44) N/A 0.36 European 392 956 N/A Hospital based
Zajac 201227 1.33 (1.12 to 1.58) 0.001 N/A European 152 100 N/A Hospital based
Yoneda 201352 1.64 (0.81 to 3.28) 0.450 0.45 Asian 125 200 All Population based
Peng 201341 1.6 (1.21 to 2.13) 0.001 N/A European, 
Asian
2069 4546 N/A Walsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Knappskog 
2012, Yoneda 2013
1.87 (1.29 to 2.73) 0.010 N/A European 1842 4251 N/A
Zhao 201453 1.41 (1.04 to 1.92) 0.030 N/A European, 
Asian
1278 2189 N/A Walsh 2007, Terry 2008, Ashton 2009, Ueda 2009, Zajac 2012, 
Yoneda 2013
1.34 (1.07 to 1.69) N/A N/A European 859 1707 N/A
Wang 201438 1.32 (1.06 to 1.64) 0.010 N/A European, 
Asian
1967 4460 N/A Walsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, 
Zajac 2012, Knappskog 2012, Yoneda 2013
1.14 (0.79 to 1.65) 0.490 N/A European 1769 4172 N/A
Xue 201642 1.46 (1.25 to 1.72) N/A N/A European 1690 4151 N/A Walsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, 
Zajac 2012, Knappskog 2012, Yoneda 2013
Zhang 201854 1.91 (1.5 to 3.47) 0.035 N/A European, 
Asian
762 1041 N/A Walsh 2007, Terry 2008, Ashton 2009, Nunobiki 2009, Ueda 2009, 
Zajac 2012
Zou 201855 1.23 (1.06 to 1.41) 0.005 N/A European, 
Asian, mixed
3535 6476 All Walsh 2007, Terry 2008, Ashton 2009, Ueda 2009, Knappskog 2012, 
Zajac 2012, Yoneda 2013, Okamoto 2015, Gansmo 201737
*Walsh et al 2007 and Gansmo et al 2017 did not meet eligibility criteria for us to include in our evaluation.
EAF, effect allele frequency; EC, endometrial cancer; SNP, single nucleotide polymorphism.
(transcriptional activator). Three SNPs have been identified in 
or around KLF5 that are associated with endometrial cancer. 
The G allele of rs11841589 (OR 1.15, 95% CI 1.11 to 1.21; 
p=4.83×10-11), the A allele of rs9600103 (OR 1.23, 95% CI 
1.16 to 1.30; p=3.76×10-12) and C allele of rs7981863 (OR 
1.16, 95% CI 1.12 to 1.20; p=2.70×10-17) have all been found 
to be associated with an increased likelihood of endometrial 
cancer in large European cohorts.21 30 34 It is worth noting that 
these SNPs are not independent, and hence they quite possibly 
tag the same causal variant.
The MYC family of proto- oncogenes encode transcription 
factors that regulate cell proliferation, which can contribute 
to cancer development if dysregulated. The recent GWAS by 
O’Mara et al reported three SNPs within the MYC region that 
reached genome- wide significance with conditional p values 
reaching at least 5×10–8.35
To test the utility of these SNPs as predictive markers, we 
devised a theoretical PRS calculation using the log ORs and 
EAFs per SNP from the published data. The results were very 
encouraging with an RR of 3.16 for the top 1% versus the mean, 
using all the top SNPs presented in table 1 and 2.09 when using 
only the SNPs that reached genome- wide significance (including 
AKT1).
Controversy surrounding MDM2 variant snP309
MDM2 negatively regulates tumour suppressor gene TP53, and 
as such, has been extensively studied in relation to its potential 
role in predisposition to endometrial cancer. Our search iden-
tified six original studies of the association between MDM2 
SNP rs2279744 (also referred to as SNP309) and endometrial 
cancer, all of which found a statistically significant increased 
risk per copy of the G allele. Two more original studies were 
identified through our full- text evaluation; however, these 
were not included here as they did not meet our inclusion 
criteria—one due to small sample size, the other due to studying 
rs2279744 status dependent on another SNP.36 37 Even so, the 
two studies were described in multiple meta- analyses that are 
listed in table 3. Different permutations of these eight orig-
inal studies appear in at least eight published meta- analyses. 
However, even the largest meta- analysis contained <2000 
cases (table 3)38
In comparison, a GWAS including nearly 13 000 cases found 
no evidence of an association with OR and corresponding 
95% CI of 1.00 (0.97 to 1.03) and a p value of 0.93 (personal 
communication).21 Nevertheless, we cannot completely rule out 
a role for MDM2 variants in endometrial cancer predisposition 
as the candidate- gene studies reported larger effects in Asians, 
whereas the GWAS primarily contained participants of European 
ancestry. There is also some suggestion that the SNP309 variant 
is in linkage disequilibrium with another variant, SNP285, which 
confers an opposite effect.
It is worth noting that the SNP285C/SNP309G haplo-
type frequency was observed in up to 8% of Europeans, thus 
requiring correction for the confounding effect of SNP285C in 
European studies.39 However, aside from one study conducted 
by Knappskog et al, no other study including the meta- analyses 
corrected for the confounding effect of SNP285.40 Among the 
studies presented in table 3, Knappskog et al (2012) reported 
that after correcting for SNP285, the OR for association of this 
haplotype with endometrial cancer was much lower, though 
still significant. Unfortunately, the meta- analyses which synthe-
sised Knappskog et al (2012), as part of their analysis, did 
not correct for SNP285C in the European- based studies they 
included.38 41 42 It is also concerning that two meta- analyses 
using the same primary articles failed to report the same result, 
in two instances.38 42–44
7Bafligil C, et al. J Med Genet 2020;0:1–10. doi:10.1136/jmedgenet-2019-106529
Cancer genetics
dIsCussIon
This article represents the most comprehensive systematic review 
to date, regarding critical appraisal of the available evidence of 
common low- penetrance variants implicated in predisposition to 
endometrial cancer. We have identified the most robust SNPs 
in the context of endometrial cancer risk. Of those, only 19 
were significant at genome- wide level and a further five were 
considered marginally significant. The largest GWAS conducted 
in this field was the discovery- and meta- GWAS by O’Mara et al, 
which utilised 12 096 cases and 108 979 controls.21 Despite the 
inclusion of all published GWAS and around 5000 newly geno-
typed cases, the total number did not reach anywhere near what 
is currently available for other common cancers such as breast 
cancer. For instance, BCAC (Breast Cancer Association Consor-
tium) stands at well over 200 000 individuals with more than 
half being cases, and resulted in identification of ~170 SNPs 
in relation to breast cancer.19 45 A total of 313 SNPs including 
imputations were then used to derive a PRS for breast cancer.19 
Therefore, further efforts should be directed to recruit more 
patients, with deep phenotypic clinical data to allow for relevant 
adjustments and subgroup analyses to be conducted for better 
precision.
A recent pre- print study by Zhang and colleagues examined 
the polygenicity and potential for SNP- based risk prediction for 
14 common cancers, including endometrial cancer, using avail-
able summary- level data from European- ancestry datasets.46 
They estimated that there are just over 1000 independent endo-
metrial cancer susceptibility SNPs, and that a PRS comprising all 
such SNPs would have an area under the receiver- operator curve 
of 0.64, similar to that predicted for ovarian cancer, but lower 
than that for the other cancers in the study. The modelling in the 
paper suggests that an endometrial cancer GWAS double the size 
of the current largest study would be able to identify suscepti-
bility SNPs together explaining 40% of the genetic variance, but 
that in order to explain 75% of the genetic variance it would be 
necessary to have a GWAS comprising close to 150 000 cases and 
controls, far in excess of what is currently feasible.
We found that the literature consists mainly of candidate- 
gene studies with small sample sizes, meta- analyses reporting 
conflicting results despite using the same set of primary arti-
cles, and multiple reports of significant SNPs that have not 
been validated by any larger GWAS. The candidate- gene studies 
were indeed the most useful and cheaper technique available 
until the mid to late 2000s. However, a lack of reproducibility 
(particularly due to population stratification and reporting bias), 
uncertainty of reported associations, and considerably high false 
discovery rates make these studies much less appropriate in the 
post- GWAS era. Unlike the candidate- gene approach, GWAS do 
not require prior knowledge, selection of genes or SNPs, and 
provide vast amounts of data. Furthermore, both the genotyping 
process and data analysis phases have become cheaper, the latter 
particularly due to faster and open- access pre- phasing and impu-
tation tools being made available.
It is clear from table 1 that some SNPs were reported with 
wide 95% CI, which can be directly attributed to small sample 
sizes particularly when restricting the cases to non- endometrioid 
histology only, low EAF or poor imputation quality. Thus, these 
should be interpreted with caution. Additionally, most of the 
SNPs reported by candidate- gene studies were not detected by 
the largest GWAS to date conducted by O’Mara et al.21 However, 
this does not necessarily mean that the possibility of those SNPs 
being relevant should be completely dismissed. Moreover, 
meta- analyses were attempted for other variants; however, 
these showed no statistically significant association and many 
presented with high heterogeneity between the respective studies 
(data not shown). Furthermore, as many studies utilised the same 
set of cases and/or controls, conducting a meta- analysis was not 
possible for a good number of SNPs. It is therefore unequivocal 
that the literature is crowded with numerous small candidate- 
gene studies and conflicting data. This makes it particularly hard 
to detect novel SNPs and conduct meaningful meta- analyses.
We found convincing evidence for 19 variants that indicated 
the strongest association with endometrial cancer, as shown in 
table 1. The associations between endometrial cancer and vari-
ants in or around HNF1B, CYP19A1, SOX4, MYC, KLF and 
EIF2AK found in earlier GWAS were then replicated in the latest 
and largest GWAS. These SNPs showed promising potential in 
a theoretical PRS we devised based on published data. Using all 
24 or genome- wide significant SNPs only, women with a PRS in 
the top 1% of the distribution would be predicted to have a risk 
of endometrial cancer 3.16 and 2.09 times higher than the mean 
risk, respectively.
However, the importance of these variants and relevance 
of the proximate genes in a functional or biological context is 
challenging to evaluate. Long distance promoter regulation by 
enhancers may disguise the genuine target gene. In addition, 
enhancers often do not loop to the nearest gene, further compli-
cating the relevance of nearby gene(s) to a GWAS hit. In order to 
elucidate biologically relevant candidate target genes in endome-
trial cancer, O’Mara et al looked into promoter- associated chro-
matin looping using a modern HiChIP approach.47 The authors 
utilised normal and tumoural endometrial cell lines for this anal-
ysis which showed significant enrichment for endometrial cancer 
heritability, with 103 candidate target genes identified across 
the 13 risk loci identified by the largest ECAC GWAS. Notable 
genes identified here were CDKN2A and WT1, and their anti-
sense counterparts. The former was reported to be nearby of 
rs1679014 and the latter of rs10835920, as shown in table 1. 
Moreover, of the 36 candidate target genes, 17 were found to 
be downregulated while 19 were upregulated in endometrial 
tumours.
The authors also investigated overlap between the 13 endome-
trial cancer risk loci and top eQTL variants for each target gene.47 
In whole blood, of the two particular lead SNPs, rs8822380 at 
17q21.32 was a top eQTL for SNX11 and HOXB2, whereas 
rs937213 at 15q15.1 was a top eQTL for SRP14. In endome-
trial tumour, rs7579014 at 2p16.1 was found to be a top eQTL 
for BCL11A. This is particularly interesting because BCL11A 
was the only nearby/candidate gene that had a GWAS associ-
ation reported in both endometrioid and non- endometrioid 
subtypes. The study looked at protein–protein interactions 
between endometrial cancer drivers and candidate target gene 
products. Significant interactions were observed with TP53 
(most significant), AKT, PTEN, ESR1 and KRAS, among others. 
Finally, when 103 target candidate genes and 387 proteins were 
combined together, 462 pathways were found to be significantly 
enriched. Many of these are related to gene regulation, cancer, 
obesity, insulinaemia and oestrogen exposure. This study clearly 
showed a potential biological relevance for some of the SNPs 
reported by ECAC GWAS in 2018.
Most of the larger included studies used cohorts primarily 
composed of women of broad European descent. Hence, there 
are negligible data available for other ethnicities, particularly 
African women. This is compounded by the lack of reference 
genotype data available for comparative analysis, making it 
harder for research to be conducted in ethnicities other than 
Europeans. This poses a problem for developing risk prediction 
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models that are equally valuable and predictive across popula-
tions. Thus, our results also are of limited applicability to non- 
European populations.
Furthermore, considering that non- endometrioid cases 
comprise a small proportion (~20%) of all endometrial cancer 
cases, much larger cohort sizes are needed to detect any genuine 
signals for non- endometrioid tumours. Most of the evalu-
ated studies looked at either overall/mixed endometrial cancer 
subtypes or endometrioid histology, and those that looked at 
variant associations with non- endometrioid histology were 
unlikely to have enough power to detect any signal with statis-
tical significance. This is particularly concerning because non- 
endometrioid subtypes are biologically aggressive tumours with 
a much poorer prognosis that contribute disproportionately to 
mortality from endometrial cancer. It is particularly important 
that attempts to improve early detection and prevention of 
endometrial cancer focus primarily on improving outcomes 
from these subtypes. It is also worth noting that, despite the 
current shift towards a molecular classification of endometrial 
cancer, most studies used the overarching classical Bokhman’s 
classification system, type I versus type II, or no histological clas-
sification system at all. Therefore, it is important to create and 
follow a standardised and comprehensive classification system 
for reporting tumour subtypes for future studies.
This study compiled and presented available information for 
an extensively studied, yet unproven in large datasets, SNP309 
variant in MDM2. Currently, there is no convincing evidence 
for an association between this variant and endometrial cancer 
risk. Additionally, of all the studies, only one accounted for the 
opposing effect of a nearby variant SNP285 in their analyses. 
Thus, we conclude that until confirmed by a sufficiently large 
GWAS, this variant should not be considered significant in influ-
encing the risk of endometrial cancer and therefore not included 
in a PRS. This is also true for the majority of the SNPs reported 
in candidate- gene studies, as the numbers fall far short of being 
able to detect genuine signals.
This systematic review presents the most up- to- date evidence 
for endometrial cancer susceptibility variants, emphasising the 
need for further large- scale studies to identify more variants of 
importance, and validation of these associations. Until data from 
larger and more diverse cohorts are available, the top 24 SNPs 
presented here are the most robust common genetic variants 
that affect endometrial cancer risk. The multiplicative effects of 
these SNPs could be used in a PRS to allow personalised risk 
prediction models to be developed for targeted screening and 
prevention interventions for women at greatest risk of endome-
trial cancer.
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